Percorten-V Injectable for Dogs (Addison's Disease Treatment) Elanco Animal Health - Safe.Pharmacy|H

Percorten-V for Dogs

by Elanco Animal Health

Percorten-V (desoxycorticosterone pivalate) is used as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency (Addison’s Disease). Canine Addison's Disease (hypoadrenocorticism) is a condition in which a dog's adrenal glands aren't working properly. Adrenal glands produce chemicals and hormones that help regulate many bodily functions such as metabolism, blood pressure and stress response. Percorten-V contains 25mg/ml desoxycorticosterone pivalate, which is recognized as having the same qualitative effects as the natural hormone aldosterone. The beginning dose may be recommended at 1 mg per pound of body weight every 25 days. Percorten-V increases the rate of sodium absorption and enhances potassium excretion. Percorten-V also increases extracellular fluid volume, which expands blood volume and improves the venous return to the heart and cardiac output. This effect prevents the life-threatening hypotensive shock and prerenal azotemia observed in animals suffering from hypoadrenocorticism. Desoxycorticosterone pivalate.

This product is labeled for storage at room temperature and will ship Monday through Thursday only. Seasonally product will be shipped in an insulated box with ice pack or soft pack. In extreme weather conditions, you may wish to upgrade to next day air for $22.50. We are unable to accept returned prescription drugs due to federal law.

Enter SAVE15 at checkout for 15% off this item.

Minimum Advertised Pricing (MAP) is the lowest advertised price allowed by the manufacturer.
MAP PRICE Minimum Advertised Pricing (MAP)
is the lowest advertised price
allowed by the manufacturer.
Item: 783RX Size: 25 mg/ml 4 ml $184.99 Shipping: FREE

Auto-Ship eligible.
Enroll for scheduled deliveries here or at checkout.



Special Edition
Digital Catalog


Commonly Purchased Products

Our Terms of Use and Privacy Policy have changed. By continuing to browse this site, you agree to the Terms of Use and Privacy Policy.